Reports from Memorial Sloan-Kettering Cancer Center Provide New Insights into Xenografts (Patient-derived-xenografts In Mice: a Preclinical Platform for Cancer Research).

A recent article from Clinical Oncology Week discusses the use of patient-derived xenografts (PDXs) in cancer research. PDXs are preclinical models that accurately reproduce the characteristics and genomic profile of parental tumors, making them valuable tools for drug development programs. However, PDXs have limitations, such as the inability to capture tumor heterogeneity and the role of the immune system. The article reviews the historical milestones of PDX implementation, recent innovations in the field, and future avenues for improvement. The research was conducted by Memorial Sloan-Kettering Cancer Center and has been peer-reviewed. [Extracted from the article]

Copyright of Clinical Oncology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)